The researchers found that in 34 patients with advanced pancreatic cancer randomly assigned to receive the anti–PD-1 therapy nivolumab with two chemotherapy drugs, nab-paclitaxel and gemcitabine, had a 1-year survival rate of 57.7%, significantly greater than the historical average of 35% with chemotherapy alone. The findings also included the identification of immune system biomarkers associated with better outcomes. A second treatment of the CD40 agonistic antibody sotigalimab with chemotherapy also appeared more effective in a subgroup of patients, identified with a different set of biomarkers. Read more . . .
Combinations of chemotherapy and immunotherapy showed activity in patients with metastatic pancreatic cancer, according to findings from a national, randomized clinical trial led and sponsored by the Parker Institute for Cancer Immunotherapy. The results of the small trial were presented by Padrón et al at the 2022 ASCO Annual Meeting (Abstract 4010) and simultaneously published in Nature Medicine.